Melatonin MT1 and MT2 receptor expression in Parkinson's disease

Nikhil Adi, Deborah C Mash, Yousuf Ali, Carlos Singer, Lina Shehadeh, Spyridon Papapetropoulos

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Background: Idiopathic Parkinson disease (PD) is a multi-system disorder with a multifactorial etiology and diverse clinical phenotype. Selective, regional dopaminergic neuronal degeneration in the substantia nigra and other CNS areas including the amygdala are observed in all patients. Apoptotic mechanisms resulting from oxidative stress and mitochondrial dysfunction have been implicated in the pathogenesis of the disease. Although the role of melatonin, a potent endogenous antioxidant, has been highlighted in PD there is no data on the expression of melatonin receptors in affected CNS regions. Material/Methods: We conducted an RT-PCR-based study to determine the MT1 and MT2 receptors expression in whole brain post-mortem tissue from the amygdala and substantia nigra of well-characterized PD and control subjects. Results: PD cases showed a statistically significant decrease of MT1 receptor expression in both substantia nigra (FC=5.11; p<0.05) and the amygdala (FC=3.11; p<0.001) versus normal controls. The expression of MT2 receptor expression was also decreased in both substantia nigra (FC=3.90; p<0.0001) and the amygdala (FC=1.91; p<0.001) versus normal controls. Conclusions: The results demonstrate a down-regulation of melatonin receptors in regions affected by PD, suggesting their possible involvement in the disease process. Future studies are needed to elucidate the role of melatonin and its receptors in the treatment/pathogenesis of PD.

Original languageEnglish
JournalMedical Science Monitor
Volume16
Issue number2
StatePublished - Feb 11 2010

Fingerprint

Melatonin MT1 Receptor
Melatonin MT2 Receptor
Parkinson Disease
Substantia Nigra
Melatonin Receptors
Amygdala
Melatonin
Oxidative Stress
Down-Regulation
Antioxidants
Phenotype
Polymerase Chain Reaction
Brain

Keywords

  • Gene expression
  • Melatonin receptors
  • mRNA
  • Parkinson's disease
  • Postmortem brain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Melatonin MT1 and MT2 receptor expression in Parkinson's disease. / Adi, Nikhil; Mash, Deborah C; Ali, Yousuf; Singer, Carlos; Shehadeh, Lina; Papapetropoulos, Spyridon.

In: Medical Science Monitor, Vol. 16, No. 2, 11.02.2010.

Research output: Contribution to journalArticle

Adi, Nikhil ; Mash, Deborah C ; Ali, Yousuf ; Singer, Carlos ; Shehadeh, Lina ; Papapetropoulos, Spyridon. / Melatonin MT1 and MT2 receptor expression in Parkinson's disease. In: Medical Science Monitor. 2010 ; Vol. 16, No. 2.
@article{6acbbae6114b4424bef346edde436d13,
title = "Melatonin MT1 and MT2 receptor expression in Parkinson's disease",
abstract = "Background: Idiopathic Parkinson disease (PD) is a multi-system disorder with a multifactorial etiology and diverse clinical phenotype. Selective, regional dopaminergic neuronal degeneration in the substantia nigra and other CNS areas including the amygdala are observed in all patients. Apoptotic mechanisms resulting from oxidative stress and mitochondrial dysfunction have been implicated in the pathogenesis of the disease. Although the role of melatonin, a potent endogenous antioxidant, has been highlighted in PD there is no data on the expression of melatonin receptors in affected CNS regions. Material/Methods: We conducted an RT-PCR-based study to determine the MT1 and MT2 receptors expression in whole brain post-mortem tissue from the amygdala and substantia nigra of well-characterized PD and control subjects. Results: PD cases showed a statistically significant decrease of MT1 receptor expression in both substantia nigra (FC=5.11; p<0.05) and the amygdala (FC=3.11; p<0.001) versus normal controls. The expression of MT2 receptor expression was also decreased in both substantia nigra (FC=3.90; p<0.0001) and the amygdala (FC=1.91; p<0.001) versus normal controls. Conclusions: The results demonstrate a down-regulation of melatonin receptors in regions affected by PD, suggesting their possible involvement in the disease process. Future studies are needed to elucidate the role of melatonin and its receptors in the treatment/pathogenesis of PD.",
keywords = "Gene expression, Melatonin receptors, mRNA, Parkinson's disease, Postmortem brain",
author = "Nikhil Adi and Mash, {Deborah C} and Yousuf Ali and Carlos Singer and Lina Shehadeh and Spyridon Papapetropoulos",
year = "2010",
month = "2",
day = "11",
language = "English",
volume = "16",
journal = "Medical Science Monitor",
issn = "1234-1010",
publisher = "International Scientific Literature Inc.",
number = "2",

}

TY - JOUR

T1 - Melatonin MT1 and MT2 receptor expression in Parkinson's disease

AU - Adi, Nikhil

AU - Mash, Deborah C

AU - Ali, Yousuf

AU - Singer, Carlos

AU - Shehadeh, Lina

AU - Papapetropoulos, Spyridon

PY - 2010/2/11

Y1 - 2010/2/11

N2 - Background: Idiopathic Parkinson disease (PD) is a multi-system disorder with a multifactorial etiology and diverse clinical phenotype. Selective, regional dopaminergic neuronal degeneration in the substantia nigra and other CNS areas including the amygdala are observed in all patients. Apoptotic mechanisms resulting from oxidative stress and mitochondrial dysfunction have been implicated in the pathogenesis of the disease. Although the role of melatonin, a potent endogenous antioxidant, has been highlighted in PD there is no data on the expression of melatonin receptors in affected CNS regions. Material/Methods: We conducted an RT-PCR-based study to determine the MT1 and MT2 receptors expression in whole brain post-mortem tissue from the amygdala and substantia nigra of well-characterized PD and control subjects. Results: PD cases showed a statistically significant decrease of MT1 receptor expression in both substantia nigra (FC=5.11; p<0.05) and the amygdala (FC=3.11; p<0.001) versus normal controls. The expression of MT2 receptor expression was also decreased in both substantia nigra (FC=3.90; p<0.0001) and the amygdala (FC=1.91; p<0.001) versus normal controls. Conclusions: The results demonstrate a down-regulation of melatonin receptors in regions affected by PD, suggesting their possible involvement in the disease process. Future studies are needed to elucidate the role of melatonin and its receptors in the treatment/pathogenesis of PD.

AB - Background: Idiopathic Parkinson disease (PD) is a multi-system disorder with a multifactorial etiology and diverse clinical phenotype. Selective, regional dopaminergic neuronal degeneration in the substantia nigra and other CNS areas including the amygdala are observed in all patients. Apoptotic mechanisms resulting from oxidative stress and mitochondrial dysfunction have been implicated in the pathogenesis of the disease. Although the role of melatonin, a potent endogenous antioxidant, has been highlighted in PD there is no data on the expression of melatonin receptors in affected CNS regions. Material/Methods: We conducted an RT-PCR-based study to determine the MT1 and MT2 receptors expression in whole brain post-mortem tissue from the amygdala and substantia nigra of well-characterized PD and control subjects. Results: PD cases showed a statistically significant decrease of MT1 receptor expression in both substantia nigra (FC=5.11; p<0.05) and the amygdala (FC=3.11; p<0.001) versus normal controls. The expression of MT2 receptor expression was also decreased in both substantia nigra (FC=3.90; p<0.0001) and the amygdala (FC=1.91; p<0.001) versus normal controls. Conclusions: The results demonstrate a down-regulation of melatonin receptors in regions affected by PD, suggesting their possible involvement in the disease process. Future studies are needed to elucidate the role of melatonin and its receptors in the treatment/pathogenesis of PD.

KW - Gene expression

KW - Melatonin receptors

KW - mRNA

KW - Parkinson's disease

KW - Postmortem brain

UR - http://www.scopus.com/inward/record.url?scp=76049109954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76049109954&partnerID=8YFLogxK

M3 - Article

C2 - 20110911

AN - SCOPUS:76049109954

VL - 16

JO - Medical Science Monitor

JF - Medical Science Monitor

SN - 1234-1010

IS - 2

ER -